Tessera Therapeutics
Urjita Tendolkar is a skilled scientific professional with extensive experience in research and development within the biotechnology sector. Currently serving as a Senior Research Associate at Tessera Therapeutics since July 2023, Tendolkar previously held similar roles at TCR² Therapeutics Inc. from June 2021 to July 2023 and at Takeda, where responsibilities included establishing and optimizing high-throughput expression and purification platforms for therapeutic drug discovery. Prior to these positions, experiences included contributions to upstream cell culture process development at Acceleron Pharma, in vitro studies at Cocoon Biotech, and academic peer tutoring at Northeastern University. Urjita Tendolkar holds a Master's degree in Biotechnology and a Bachelor of Science in Cellular and Molecular Biology, both from Northeastern University, as well as an International Baccalaureate Diploma from SVKM International School.
Tessera Therapeutics
3 followers
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.